BridgeBio Pharma

Últimas notícias

Manchetes no idioma original da fonte.

• The Speak Foundation Announces $300,000 BridgeBio Commitment to Advance Patient-Led LGMD Centers of Excellence (abre em uma nova aba)

  PR Newswire · 1 de out. de 2026

• Barclays Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $157 (abre em uma nova aba)

  Moomoo · 30 de set. de 2026

• (BBIO) Movement as an Input in Quant Signal Sets (abre em uma nova aba)

  Stock Traders Daily · 30 de set. de 2026

• Debt to assets ratio of BridgeBio Pharma, Inc. – HAN:2CL (abre em uma nova aba)

  TradingView · 29 de set. de 2026

• BridgeBio Pharma, Inc. Revenue Breakdown – HAN:2CL (abre em uma nova aba)

  TradingView · 29 de set. de 2026

• BridgeBio Pharma (BBIO) Following Acoramidis Study Faces A Wide Fair Value Debate (abre em uma nova aba)

  Simply Wall Street · 28 de set. de 2026

• Real World Heart Study Altering The Investment Case For BridgeBio Pharma Stock? (abre em uma nova aba)

  Simply Wall Street · 26 de set. de 2026

• BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status (abre em uma nova aba)

  Yahoo Finance · 26 de set. de 2026

• BridgeBio Pharma (BBIO) Reports 34% Lower Risk Of Early Clinical Worsening (abre em uma nova aba)

  Simply Wall Street · 25 de set. de 2026

• BridgeBio Pharma (BBIO) Short Interest & Short Float | Updated Sep 2026 (abre em uma nova aba)

  MarketBeat · 24 de set. de 2026

• Why BridgeBio Pharma (BBIO) Stock Is Down Today (abre em uma nova aba)

  Quiver Quantitative · 23 de set. de 2026

• BBIO Looks 56.2% Undervalued on GF Value™ Despite Profitability Challenges (abre em uma nova aba)

  GuruFocus · 23 de set. de 2026

• BridgeBio says heart disease therapy Attruby beat Pfizer’s Vyndamax in real world study (abre em uma nova aba)

  Seeking Alpha · 23 de set. de 2026

• BridgeBio Pharma Announces Real-World Study Showing Acoramidis Reduced Clinical Worsening Versus Tafamidis in ATTR-CM (abre em uma nova aba)

  Quiver Quantitative · 23 de set. de 2026

• BridgeBio Pharma (BBIO) Stock Looks Properly Priced For Its Sales Story (abre em uma nova aba)

  Simply Wall Street · 23 de set. de 2026

• BridgeBio Pharma stock finds support near USD 66 (abre em uma nova aba)

  AD HOC NEWS · 23 de set. de 2026

• BridgeBio (NASDAQ: BBIO) CEO’s trust sells 10,000 shares under preset plan (abre em uma nova aba)

  Stock Titan · 21 de set. de 2026

• 7 Red Days In A Row: BridgeBio Pharma Stock Is Down 12% (abre em uma nova aba)

  Trefis · 21 de set. de 2026

• BridgeBio Pharma CEO Neil Kumar sells $690,847 in shares (abre em uma nova aba)

  Investing.com · 21 de set. de 2026

• BridgeBio Pharma stock gains attention as fresh inducement grants highlight growth plans (abre em uma nova aba)

  AD HOC NEWS · 19 de set. de 2026

• BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (abre em uma nova aba)

  The Manila Times · 19 de set. de 2026

• Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT) (abre em uma nova aba)

  The Globe and Mail · 11 de set. de 2026

• How Achondroplasia NDA Progress Will Impact BridgeBio Pharma Stock (abre em uma nova aba)

  Simply Wall Street · 11 de set. de 2026

• BridgeBio Pharma's drug successes boost valuati... (abre em uma nova aba)

  Pluang · 10 de set. de 2026

• BridgeBio at Cantor global healthcare conference: launch pipeline in focus By Investing.com (abre em uma nova aba)

  Investing.com UK · 10 de set. de 2026

• BridgeBio Pharma: Attruby Peak Sales Set To Rise (abre em uma nova aba)

  Seeking Alpha · 10 de set. de 2026

• BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound? (abre em uma nova aba)

  Yahoo Finance · 9 de set. de 2026

• BridgeBio (BBIO) Reported Signs of Cardiac Reversal With Acoramidis. How Much Weight Should Investors Give a Completer Analysis? (abre em uma nova aba)

  Yahoo Finance · 4 de set. de 2026

• Lionsbridge takes $704K stake in BridgeBio Pharma as analysts turn bullish (abre em uma nova aba)

  Dealroom · 2 de set. de 2026